Table 5.
Clinical trial study
| Type of Study | Nanohybrids | Size | Phase study | Purpose/Condition | Study Status | Clinical trial number | URL |
|---|---|---|---|---|---|---|---|
| Single dose efficacy study of AuroLase® Therapy in the metastatic lung tumor treatment | Polyethylene glycol coated gold nanoshell nanomaterial Auroshell® used to enhance photothermal therapy through Near Infrared laser irradiation method | 120-150 nm | Not applicable | To treat lung cancer, metastatic lung tumor, lung neoplasm, | First posted: 13.08.2012 Completion date: 3.11.2016 (terminated) |
NCT01679470 | https://www.clinicaltrials.gov/study/NCT01679470?term=NCT01679470&rank=1 |
| 15 nm | Refractory or recurrent tumor of the head and neck | First posted: 20.02.2009 Completion: 09.02.2017 (completed) |
NCT00848042 | https://www.clinicaltrials.gov/study/NCT00848042?term=NCT00848042&rank=1 | |||
| Neoplasm of the prostate tissue | First submitted: 02.2016 Final Submitted:03.03.2021 (not recruiting) |
NCT02680535 | https://www.clinicaltrials.gov/study/NCT02680535?term=NCT02680535&rank=1 | ||||
| First submission: 30.01.2020 Final Submission: 18.05.2023 (recruiting) |
NCT04240639 | https://www.clinicaltrials.gov/study/NCT04240639?term=NCT04240639&rank=1 | |||||
| Doxorubicin Hydrochloride Injection Lipodox® Caelyx® Bioequivalence Study in Patients with Breast and Ovarian Cancer | The free and encapsulated doxorubicin concentrations in plasma were measured using two different, verified liquid chromatography-mass spectrometry analytical techniques. | 90 nm | Phase I | Breast and Ovarian cancer | First posted: 28.07.2021 Final posted: 10.03.2022 |
NCT05273944 | https://www.clinicaltrials.gov/study/NCT05273944?term=NCT05273944&rank=1 |